GENNEXPharmaceuticals
Gennex Laboratories Ltd — Cash Flow Statement
₹7.13
-11.88%
Gennex Laboratories Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -19.74 Cr | -46.69 Cr | -16.11 Cr | 10.31 Cr | — |
| Issuance Of Capital Stock | 0.00 | 79.83 Cr | 30.44 Cr | 0.00 | — |
| Capital Expenditure | -8.95 Cr | — | -39.79 Cr | -1.59 Cr | -0.08 Cr |
| End Cash Position | 55.57 Cr | 60.98 Cr | 15.06 Cr | 8.68 Cr | — |
| Beginning Cash Position | 60.98 Cr | 15.06 Cr | 8.68 Cr | 1.07 Cr | — |
| Changes In Cash | -5.41 Cr | 45.91 Cr | 6.38 Cr | 7.61 Cr | — |
| Financing Cash Flow | 4.57 Cr | 73.68 Cr | 21.03 Cr | -1.83 Cr | — |
| Interest Paid Cff | -3.61 Cr | -3.08 Cr | -1.35 Cr | -0.88 Cr | — |
| Net Common Stock Issuance | 0.00 | 79.83 Cr | 30.44 Cr | 0.00 | — |
| Common Stock Issuance | 0.00 | 79.83 Cr | 30.44 Cr | 0.00 | — |
| Net Issuance Payments Of Debt | 8.17 Cr | -3.07 Cr | -8.05 Cr | -0.95 Cr | — |
| Net Short Term Debt Issuance | 4.50 Cr | 0.00 | -9.07 Cr | -0.94 Cr | — |
| Net Long Term Debt Issuance | 3.68 Cr | -3.07 Cr | 1.02 Cr | -0.02 Cr | — |
| Investing Cash Flow | 0.82 Cr | 18.91 Cr | -38.33 Cr | -2.47 Cr | — |
| Interest Received Cfi | 9.57 Cr | 3.79 Cr | 2.66 Cr | -0.90 Cr | — |
| Net PPE Purchase And Sale | -8.75 Cr | 15.35 Cr | -39.74 Cr | -1.57 Cr | — |
| Sale Of PPE | 0.20 Cr | 15.35 Cr | 0.05 Cr | 0.03 Cr | — |
| Purchase Of PPE | -8.95 Cr | 0.00 | -39.79 Cr | -1.59 Cr | — |
| Operating Cash Flow | -10.80 Cr | -46.69 Cr | 23.68 Cr | 11.91 Cr | — |
| Taxes Refund Paid | -3.22 Cr | 0.00 | 0.00 | -1.11 Cr | — |
| Change In Working Capital | -25.00 Cr | -64.83 Cr | 17.69 Cr | 5.18 Cr | — |
| Change In Other Current Liabilities | 1.77 Cr | -49.00 Cr | 0.53 Cr | — | — |
| Change In Other Current Assets | -17.64 Cr | -9.48 Cr | 11.30 Cr | 4.79 Cr | — |
| Change In Payable | -2.02 Cr | 2.05 Cr | 12.45 Cr | 5.47 Cr | — |
| Change In Inventory | -10.77 Cr | -8.39 Cr | -7.96 Cr | -2.72 Cr | — |
| Change In Receivables | 3.65 Cr | -8.39 Cr | 1.90 Cr | -2.37 Cr | — |
| Other Non Cash Items | -5.96 Cr | -0.72 Cr | -1.31 Cr | 1.78 Cr | — |
| Depreciation And Amortization | 1.99 Cr | 2.37 Cr | 0.92 Cr | 0.79 Cr | — |
| Depreciation | 1.99 Cr | 2.37 Cr | 0.92 Cr | 0.79 Cr | — |
| Net Income From Continuing Operations | 21.40 Cr | 16.49 Cr | 6.37 Cr | 5.28 Cr | — |
| Repayment Of Debt | — | -3.07 Cr | -9.07 Cr | -3.70 Cr | -0.02 Cr |
| Issuance Of Debt | — | 0.00 | 1.02 Cr | 2.76 Cr | 0.00 |
| Long Term Debt Payments | — | -3.07 Cr | — | -0.02 Cr | -0.02 Cr |
| Long Term Debt Issuance | — | 0.00 | 1.02 Cr | 0.00 | 0.00 |
| Net Other Investing Changes | — | -0.23 Cr | -1000.00 | — | — |
| Net Investment Purchase And Sale | — | 0.00 | -1.25 Cr | 0.00 | — |
| Purchase Of Investment | — | 0.00 | -1.25 Cr | 0.00 | — |
| Other Cash Adjustment Outside Changein Cash | — | — | -1000.00 | — | 1000.00 |
| Short Term Debt Payments | — | — | -9.07 Cr | -3.70 Cr | — |
| Gain Loss On Investment Securities | — | — | -0.05 Cr | — | — |
| Short Term Debt Issuance | — | — | — | 2.76 Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Gennex Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.